Introduced in the late 1990s for non-Hodgkin's lymphoma, the anti-CD20 monoclonal antibody rituximab has had anecdotal success in several renal settings. Here, Salama and Pusey compile and evaluate the data supporting use of rituximab to manage post-transplantation lymphoproliferative disorder, graft rejection, and ABO- and HLA-incompatibility. The drug's potential utility in autoimmune conditions that affect the kidney, including focal segmental glomerulosclerosis and systemic lupus erythematosus, is also assessed.
- Alan D Salama
- Charles D Pusey
